<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04208308</url>
  </required_header>
  <id_info>
    <org_study_id>UEM001LFPJSU</org_study_id>
    <nct_id>NCT04208308</nct_id>
  </id_info>
  <brief_title>Omega-3 PUFA in Prevention of Cardiovascular and Metabolic Diseases (CARDMET3)</brief_title>
  <acronym>CARDMET3</acronym>
  <official_title>Comparison of Effect of Animal and Plant Sources of Omega-3 PUFA in Prevention of Cardiovascular and Metabolic Diseases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pavol Jozef Safarik University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pavol Jozef Safarik University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is aimed to assess the efficacy of animal, plant sources of omega-3 polyunsaturated
      fatty acids and omega-3 pharmacological supplements on obesity, metabolic syndrome and
      cardiovascular disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      More than four million people in Europe (47%) and more than 1.9 million people in European
      Union (EU) (40%) die of cardiovascular diseases (CVD) every year. CVD mortality in EU is 43%
      in women and 36% in men. In Central and Eastern Europe, much more people die of CVD than in
      Western, Northern and Southern European countries. The World Health Organization (WHO) states
      that number of deaths in Slovakia is much higher than in Western European countries, even
      higher than in V4 countries - Slovakia, Czech Republic, Poland and Hungary

      In the first stage of the project fatty acids will be analyzed with the focus on the ratio of
      omega-6 and omega-3 polyunsaturated fatty acids in fatty food for normal consumption and in
      nutritional supplements containing omega-3 polyunsaturated fatty acids.

      In the second phase of the project risk factors of cardiovascular diseases for people without
      and people with a history of cardiovascular disease will be monitored and compared. There
      will be monitored and compared a wide range of laboratory markers of clinical biochemistry,
      immunology, pathological physiology in order to determine cardiovascular risk for men and
      women in different age categories.

      The third stage will monitor the effect of natural plant and animal sources and
      pharmacological nutritional supplements with omega-3 polyunsaturated fatty acids on obesity,
      metabolic syndrome and cardiovascular risk factors.

      The aim of this study is to assess the efficacy of animal, plant sources of omega-3
      polyunsaturated fatty acids and omega-3 pharmacological supplements on obesity, metabolic
      syndrome and cardiovascular disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2013</start_date>
  <completion_date type="Anticipated">December 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Healthy and obese people in different age categories.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body mass index</measure>
    <time_frame>6 months</time_frame>
    <description>BMI kg/m2 6 months change.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>glucose levels</measure>
    <time_frame>6 months</time_frame>
    <description>fasting glucose in mmoL/L</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in total cholesterol from baseline</measure>
    <time_frame>6 months</time_frame>
    <description>percentual change in total cholesterol (mmoL/L) from baseline to 6months followup
- total genetic analysis, extracellular DNA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic inflammation activity</measure>
    <time_frame>1 months</time_frame>
    <description>Interleukin 1 levels, interleukin 6 levels (pg/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antioxidant status</measure>
    <time_frame>18 months</time_frame>
    <description>Determination of total antioxidant capacity (mmoL/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in estrogen concentration</measure>
    <time_frame>6 months</time_frame>
    <description>Assesment of concentration of estrogen (ng/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bile acids in serum</measure>
    <time_frame>6 months</time_frame>
    <description>Concentration of serum bile acids (pg/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tissue concentrations of nitric oxide</measure>
    <time_frame>6months</time_frame>
    <description>Determination of nitric oxide synthetase activity by electron microscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NF kappa B activity</measure>
    <time_frame>6 months</time_frame>
    <description>Determination of NF kappa B activity by electron microscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Catalase activity</measure>
    <time_frame>6 months</time_frame>
    <description>Determination of Catalase activity by electron microscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Superoxide dismutase activity</measure>
    <time_frame>6 months</time_frame>
    <description>Determination of Superoxide dismutase activity by electron microscopy</description>
  </primary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Obesity, Abdominal</condition>
  <condition>Metabolic Syndrome</condition>
  <condition>Cardiovascular Risk Factor</condition>
  <arm_group>
    <arm_group_label>Control negative group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Without supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental negative group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chia seeds supplementation (25 g)
On dose (25g) of chia seeds contains:
energy 498,75 kJ / 118,75 kcal, protein 3,25 g, carbohydrates 9 g, fiber 6 g, fats 6,5 g, Calcium 160 mg Phosphorus 247,5 mg Kalium 37,5 mg Natrium 5,25 mg Zincum 0,975 mg Manganum 0,625 mg Omega-3 fatty acids 4,475 g Omega-6 fatty acids 1,475 g Vitamin B1 0,1 mg Vitamin B2 0,0075 mg Vitamin B3 0,75 mg Vitamin C 0,2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental negative group II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chia seeds supplementation (15 g)
On dose (15g) of chia seeds contains:
energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental negative group III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combine supplementation: chia seeds and fish oil
Daily dose:
Chia seeds supplementation (15 g) and fish oil supplementation (pharmacological supplement) - Maxi Cor 70+20 (EPA 675 mg +DHA 510 mg)
On dose (15g) of chia seeds contains:
energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental negative group IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fish oil supplementation
Daily dose:
Fish oil supplementation (pharmacological supplemment) - Maxi Cor 70+20 (EPA 825 mg +DHA 525 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control positive group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Without supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental positive group I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chia seeds supplementation (25 g)
On dose (25g) of chia seeds contains:
energy 498,75 kJ / 118,75 kcal, protein 3,25 g, carbohydrates 9 g, fiber 6 g, fats 6,5 g, Calcium 160 mg Phosphorus 247,5 mg Kalium 37,5 mg Natrium 5,25 mg Zincum 0,975 mg Manganum 0,625 mg Omega-3 fatty acids 4,475 g Omega-6 fatty acids 1,475 g Vitamin B1 0,1 mg Vitamin B2 0,0075 mg Vitamin B3 0,75 mg Vitamin C 0,2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental positive group II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chia seeds supplementation (15 g)
On dose (15g) of chia seeds contains:
energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental positive group III</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combine supplementation: chia seeds and fish oil
Daily dose:
Chia seeds supplementation (15 g) and fish oil supplementation (pharmacological supplement) - Maxi Cor 70+20 (EPA 675 mg +DHA 510 mg)
On dose (15g) of chia seeds contains:
energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental positive group IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fish oil supplementation
Daily dose:
Fish oil supplementation (pharmacological supplemment) - Maxi Cor 70+20 (EPA 825 mg +DHA 525 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Chia seeds supplementation (25 g)</intervention_name>
    <description>Dosage: 1 daily dose energy 498,75 kJ / 118,75 kcal, protein 3,25 g, carbohydrates 9 g, fiber 6 g, fats 6,5 g, Calcium 160 mg Phosphorus 247,5 mg Kalium 37,5 mg Natrium 5,25 mg Zincum 0,975 mg Manganum 0,625 mg Omega-3 fatty acids 4,475 g Omega-6 fatty acids 1,475 g Vitamin B1 0,1 mg Vitamin B2 0,0075 mg Vitamin B3 0,75 mg Vitamin C 0,2 mg</description>
    <arm_group_label>Experimental negative group I</arm_group_label>
    <arm_group_label>Experimental positive group I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Chia seeds supplementation (15 g)</intervention_name>
    <description>Dosage: 1 daily dose energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg</description>
    <arm_group_label>Experimental negative group II</arm_group_label>
    <arm_group_label>Experimental positive group II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Combine supplementation: chia seeds (15g) and fish oil Maxi Cor 70+20</intervention_name>
    <description>Chia seeds - 1 daily dose Fish oil TID
Chia seeds supplementation (15 g) and fish oil supplementation (pharmacological supplement) - Maxi Cor 70+20 (EPA 675 mg +DHA 510 mg)
On dose (15g) of chia seeds contains:
energy 299 kJ / 71,2 kcal, protein 1,95 g, carbohydrates 5,4 g, fiber 3,6 g, fats 3,9 g, Calcium 96 mg Phosphorus 148,5 mg Kalium 22,5 mg Natrium 3,15 mg Zincum 0,59 mg Manganum 0,375 mg Omega-3 fatty acids 2,684 g Omega-6 fatty acids 0,885 g Vitamin B1 0,06 mg Vitamin B2 0,0045 mg Vitamin B3 0,45 mg Vitamin C 0,12 mg</description>
    <arm_group_label>Experimental negative group III</arm_group_label>
    <arm_group_label>Experimental positive group III</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish oil supplementation</intervention_name>
    <description>TID
Daily dose:
Fish oil supplementation (pharmacological supplemment) - Maxi Cor 70+20 (EPA 825 mg +DHA 525 mg)</description>
    <arm_group_label>Experimental negative group IV</arm_group_label>
    <arm_group_label>Experimental positive group IV</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  for obese participants were BMI≥29, age ≥18 and non-smokers, cardiovascular diseases.
             metabolic syndrome, obesity

          -  for healthy participants with normal weight, inclusion criteria BMI25, age ≥18,
             non-smokers

        Exclusion Criteria:

          -  for all participants were cancer, inflammatory diseases, tuberculosis, renal and
             hepatic insufficiency, and pregnancy

          -  for healthy participants without cardiovascular diseases, obesity and metabolic
             syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zdenka Hertelyová, Dr., PhD.</last_name>
    <role>Study Director</role>
    <affiliation>Pavol Josef Šafarik University, Faculty of Medicine, 040 11 Košice, Slovakia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zdenka Hertelyová, Dr. PhD.</last_name>
    <phone>+421552343225</phone>
    <email>zdenka.hertelyova@upjs.sk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alojz Bomba, MVDr., DrSc.</last_name>
    <phone>+421552343461</phone>
    <email>alojz.bomba@upjs.sk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>1st Department of Internal medicine, L. Pasteur University Hospital in Košice</name>
      <address>
        <city>Košice</city>
        <zip>04011</zip>
        <country>Slovakia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Janicko, MD, PhD</last_name>
      <phone>+42155640</phone>
      <phone_ext>3515</phone_ext>
      <email>interna1.snp@unlp.sk</email>
    </contact>
  </location>
  <location_countries>
    <country>Slovakia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 6, 2019</study_first_submitted>
  <study_first_submitted_qc>December 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2019</study_first_posted>
  <last_update_submitted>March 19, 2020</last_update_submitted>
  <last_update_submitted_qc>March 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pavol Jozef Safarik University</investigator_affiliation>
    <investigator_full_name>Martin Janičko</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Obesity, Abdominal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

